Cereno Scientific (DB:4A1) - Stock Price, News & Analysis

4A1 Stock Overview

Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. More details

4A1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Has less than 1 year of cash runway

Earnings have declined by 49.7% per year over past 5 years

Shareholders have been diluted in the past year

Cereno Scientific AB (publ) Competitors

Heidelberg Pharma

XTRA:HPHA

€105.8m

2invest

XTRA:2INV

€62.7m

Formycon

XTRA:FYB

€857.2m

Biotest

XTRA:BIO3

€1.3b

Price History & Performance

Summary of all time highs, changes and price drops for Cereno Scientific
Historical stock prices
Current Share Price	SEK 0.42
52 Week High	SEK 0.79
52 Week Low	SEK 0.29
Beta	0.35
11 Month Change	-14.80%
3 Month Change	-26.28%
1 Year Change	0.95%
33 Year Change	-7.21%
5 Year Change	n/a
Change since IPO	49.65%

Recent updates

Shareholder Returns

	4A1	DE Biotechs	DE Market
7D	1.7%	0.8%	0.8%
1Y	1.0%	-18.3%	8.6%

Return vs Industry: 4A1 exceeded the German Biotechs industry which returned -16.9% over the past year.

Return vs Market: 4A1 underperformed the German Market which returned 9.1% over the past year.

Price Volatility

Is 4A1's price volatile compared to industry and market?
4A1 volatility
4A1 Average Weekly Movement	12.0%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 4A1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4A1's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2012	5	Sten Sorensen	www.cerenoscientific.com

Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases.

Cereno Scientific AB (publ) Fundamentals Summary

How do Cereno Scientific's earnings and revenue compare to its market cap?
4A1 fundamental statistics
Market cap	€124.20m
Earnings (TTM)	-€7.04m
Revenue (TTM)	€7.53m

16.5x

P/S Ratio

-17.6x

P/E Ratio

Is 4A1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4A1 income statement (TTM)
Revenue	SEK 86.75m
Cost of Revenue	SEK 0
Gross Profit	SEK 86.75m
Other Expenses	SEK 167.87m
Earnings	-SEK 81.12m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 25, 2025

Earnings per share (EPS)	-0.29
Gross Margin	100.00%
Net Profit Margin	-93.51%
Debt/Equity Ratio	39.2%

How did 4A1 perform over the long term?

See historical performance and comparison

4A1 Stock Overview

Risk Analysis

Cereno Scientific AB (publ) Competitors

XTRA:HPHA

€105.8m

XTRA:2INV

€62.7m

XTRA:FYB

€857.2m

XTRA:BIO3

€1.3b

Price History & Performance

Recent News & Updates

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Recent updates

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024

Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil

First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific AB (publ) to Report Q3, 2024 Results on Nov 21, 2024

Cereno Scientific's Novel HDACi CS014 Has Potential to Become an Effective Antithrombotic Therapy in Patients with A High Risk of Thrombotic Events as Presented at the ASH Meeting

Cereno Scientific Announces New Preclinical Data Concludes That Drug Candidate CS585

Cereno Scientific Completes Preclinical Safety Program for Innovative Drug Candidate CS014 Targeting Thrombosis Prevention and Reaches A Major Preparatory Milestone Towards the Phase I Study

Cereno Scientific Obtains First Patent in India for Drug Candidate Cs1 Through Its Third Patent Family

Cereno Scientific AB (Publ) Move to Request “Compassionate Use” of CS1 for Treatment of Patients with Rare Disease PAH

Third quarter 2023 earnings released

Cereno Scientific Reports Significant Progress and A Time Time Adjustment in the Phase II Study of CS1 in Rare Disease PAH

Cereno Scientific AB (publ) Appoints Jeppe Øvlesen as a New Board Member

Cereno Scientific AB (Publ) Reports Positive Results from the Data Quality Control Review Initiative in the Phase II Study of CS1 in Rare Disease Pul Arterial Hypertension (PAH)

Cereno Scientific Announces Appointments to the Nomination Committee Ahead of the Annual General Meeting 2024

New major risk - Shareholder dilution

Second quarter 2023 earnings released

Cereno Scientific to Open Two New Clinics to Complete Patient Recruitment in the Phase II Study of CS1 in Pah

Cereno Scientific AB (Publ) Appoints Eva Jagenheim as Chief Financial Officer

Cereno Scientific Reports Positive Data from Patient Case Study

Chairperson recently bought €68k worth of stock

Cereno Scientific Reports an Investigator-Initiated Patient Case Study from the Ongoing Phase II Study of CS1 in PAH

Cereno Scientific AB (publ), Annual General Meeting, Jun 03, 2024

Cereno Scientific Shares Progress Update in the Phase II Study with Drug Candidate CS1 in the Rare Disease PAH

Cereno Scientific's Phase II Study in the Rare Disease PAH Reports Two Patients Successfully Completed the Treatment Period with Drug Candidate CS1

Full year 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in FY 2021)

Full year 2022 earnings released: kr0.26 loss per share (vs kr0.15 loss in FY 2021)

Cereno Scientific AB (publ) Reports Progress with CS1 Phase II Study in Pulmonary Arterial Hypertension

Cereno Scientific AB (publ) to Report Nine Months, 2023 Results on Nov 17, 2023

Cereno Scientific AB (Publ) Appoints Etienne Adriansen to Chief Business Officer, as of March 1, 2023

Cereno Scientific Announces Changes in the Executive Management Team

Cereno Scientific Reports Six Activated Clinical Sites and Updated Timeline in the Phase II Study in PAH with Drug Candidate CS1

Cereno Scientific AB (Publ) Announces Appointment of Nomination Committee